Institute of Respiratory Disease, Department of Translational Biomedicine and Neuroscience, University "Aldo Moro", Bari, Italy.
Institute of Respiratory Disease, Department of Translational Biomedicine and Neuroscience, University "Aldo Moro", Bari, Italy.
J Allergy Clin Immunol Pract. 2023 May;11(5):1417-1420. doi: 10.1016/j.jaip.2023.01.021. Epub 2023 Jan 30.
Defining super-response to biologic treatment is a major concern in severe asthma. Although many definitions have been proposed, there is still a gap between the clinical perception of the super-response and a standardized classification. The current definition of super-response mainly relies on several clinical features, while many aspects of severe asthma inflammation and lung function are still poorly considered. Furthermore, many criteria of severe asthma super-response overlap with those of the clinical remission, leaving room for possible misclassifications. In this context, identifying the correct trajectory linking these 2 aspects of type 2-high severe asthma could help clinicians to understand which factors can predict a greater response to biologic therapies. In this paper, we review various aspects of super-response assessment, proposing some new criteria for its definition as well as new perspectives on its relationship with severe asthma clinical remission.
定义生物治疗的超强反应是严重哮喘的一个主要关注点。尽管已经提出了许多定义，但临床对超强反应的认知与标准化分类之间仍存在差距。目前的超强反应定义主要依赖于几个临床特征，而严重哮喘炎症和肺功能的许多方面仍未得到充分考虑。此外，许多严重哮喘超强反应的标准与临床缓解的标准重叠，这可能导致分类错误。在这种情况下，确定这 2 种 2 型高反应性严重哮喘之间的正确轨迹可以帮助临床医生了解哪些因素可以预测对生物治疗的更大反应。在本文中，我们回顾了超强反应评估的各个方面，提出了一些新的定义标准，并探讨了其与严重哮喘临床缓解的关系。
